Free Trial

MHRA Recommends AZ Vaccine Not Offered To Under 30s

UK

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has recommended that the AstraZeneca COVID-19 vaccine is not offered to people under the age of 30 due to extremely rare cases of blood clots that may be linked to the vaccine.

  • Figures from MHRA chief: 79 reports of blood clots after first AstraZeneca dose (51 women / 28 men), 19 died, 3 were under 30. Equates to 4 in 1 million doses dispensed ie 'very rare'.
  • With under 30's still not due to be receiving vaccines unless they have a pre-existing condition it remains to be seen the impact of this decision on the vaccine rollout. The UK has already wound down its first dose offers in the month of April to ensure sufficient AZ vaccine supply for people's second doses.
  • The rollout of the Moderna vaccine started in Wales today, and with 17mn doses due this could provide some of the doses needed to fill the AZ gap for the under 30s.
  • Prof Wei Shen Lim, chair of the JCVI stated that "We are not advising a stop to any vaccination in any age group. We are advising a preference to a particular age group"

Slide used to justify MHRA decision

Source: MHRA

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.